AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyNot reportedTrial registry
Patient Satisfaction with Subcutaneous Ocrelizumab in RRMS Patients
The study aims to assess patient satisfaction with subcutaneous ocrelizumab administration in patients with relapsing-remitting multiple sclerosis (RRMS) over a 12-month follow-up period.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
Understanding patient satisfaction with treatment is essential for improving adherence and quality of care in MS therapies.
What this does not prove
No results are posted, and planned enrolment and endpoints do not constitute findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
Supporting passages (5)
subjects"studyPopulation": "The study population will consist of participants diagnosed with RRMS who are treated with ocrelizumab s.c.
primary endpoint"measure": "Proportion of Satisfied/Very Satisfied Responses on the Treatment Administration Satisfaction Questionnaire (TASQ) - Satisfaction Item Score at Month 12",
follow up"description": "Treatment experienced participants who were receiving prior DMTs and then switched to ocrelizumab s.c., as outlined in the protocol will be observed for 12 months to characterize participant satisfaction following initiation of ocrelizumab s.c.",
findings"briefSummary": "The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching from intravenous (i.v.) ocrelizumab to s.c.
limitationsNo results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.